Callio Therapeutics Company
Hummingbird Bio spin-out developing dual-payload antibody-drug conjugates for drug-resistant cancers; raised a US$187M Series A in 2025; offices in Singapore, Seattle and San Diego.
Technology:
PharmTech
Industry:
Advanced BioTech R&D
Sub-Industry:
PharmTech
Investors:
ClavystBio
City:
Singapore
Country:
Singapore